Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

March 3, 2025

Study Completion Date

November 15, 2025

Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
DRUG

Ifinatamab Deruxtecan (I-DXd)

I-DXd will be administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (every Q3W).

Trial Locations (58)

333

Chang Gung Memorial Hospital Linkou, Taoyuan

704

National Cheng Kung University Hospital Nckuh, Tainan City

5505

Asan Medical Center, Seoul

10002

National Taiwan University Hospital, Taipei

10065

Memorial Sloan-Kettering Cancer Center (Mskcc) - New York, New York

10408

National Cancer Center, Goyang-si

10461

Montefiore Medical Center Prime, The Bronx

11217

Taipei Veterans General Hospital, Taipei

13125

Evangelische Lungenklinik Berlin, Berlin

13620

Seoul National University Bundang Hospital, Seongnam-si

13915

Hôpital Nord - Chu Marseille, Marseille

15006

Complejo Hospitalario Universitario A Coruña, A Coruña

21287

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

27703

Duke University Health System, Durham

28034

Hospital Universitario Ramon Y Cajal, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

29011

Hospital Regional Universitario Malaga, Málaga

32256

The Cancer Specialists, Llc, Jacksonville

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

34295

CHU de Montpellier - Hôpital Arnaud de Villeneuve, Montpellier

Hopital Arnaud de Villeneuve, Montpellier

37203

Sarah Cannon (Tennessee Oncology - Nashville), Nashville

40705

Taichung Veterans General Hospital, Taichung

41009

Hospital Virgen Macarena, Seville

45147

Universitaetsklinikum Essen, Essen

48202

Henry Ford Hospital, Detroit

49503

Cancer and Hematology Centers of Western Michigan, Grand Rapids

60637

University of Chicago Medical Center, Chicago

63110

Washington University School of Medicine, St Louis

69008

Centre Leon Berard, Lyon

72762

Highlands Oncology Group, Springdale

75005

Institut Curie - Site de Paris, Paris

75020

Hopital Tenon, Paris

77090

Millennium Physicians Association, Llp, Houston

83301

Chang Gung Medical Foundation - Kaohsiung Branch, Kaohsiung City

94000

Centre Hospitalier Intercommunal de Créteil, Créteil

98195

University of Washington Medical Center, Seattle

130012

Jilin Cancer Hospital, Changchun

200032

Fudan University Shanghai Cancer Center, Shanghai

276000

Linyi Cancer Hospital, Linyi

310022

Zhejiang Cancer Hospital, Hangzhou

410013

Hunan Cancer Hospital, Changsha

430022

Union Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan

510000

Guangdong Provincial People'S Hospital, Guangdong

610041

West China Hospital, Sichuan University, Chengdu

02215

Dana-Faeber Cancer Institute, Boston

08050

Hackensack Meridian Health-Southern Ocean Medical Center, Manahawkin

104-0045

National Cancer Center Hospital, Chūōku

277-8577

National Cancer Center Hospital East, Kashiwa

135-8550

The Cancer Institute Hospital of Jfcr, Kōtoku

411-8777

Shizuoka Cancer Center, Nagaizumi-chō

541-8567

Osaka International Cancer Institute, Osaka

589-8511

Kindai University Hospital, Ōsaka-sayama

241-8515

Kanagawa Cancer Center, Yokohama

03080

Seoul National University Hospital, Seoul

06351

Samsung Medical Center, Seoul

08035

Hospital Universitario Vall Dhebron, Barcelona

08908

Ico L'Hospitalet - Hospital Duran I Reynals, L'Hospitalet de Llobregat

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Daiichi Sankyo

INDUSTRY

NCT05280470 - Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Biotech Hunter | Biotech Hunter